Dateline City:
BOSTON
Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting and Published in The Lancet
First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015
BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of results from a multi-arm Phase 2
clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742, the
companys investigational NS3/4A protease inhibitor and NS5A inhibitor,
respectively) with or without ribavirin (RBV) in treatment-nave and
previously-treated (with peg-interferon/ribavirin [PR]) patients with
chronic hepatitis C virus (HCV) genotype 1 (GT1) infection -- the C-WORTHy
study (Parts A and B).
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more